Active Biotech (ACTI.ST) publishes a new
paper* in the next issue of
the scientific journal "The Prostate", in collaboration with Dr. John
T. Isaacs of The Johns Hopkins University School of Medicine,
Baltimore, MD, USA.
The article presents pre-clinical data regarding Active Biotech's
project TASQ for the treatment of prostate cancer.
The objective for the TASQ project is to develop a pharmaceutical
product that can be administered orally for the chronic treatment of
prostate cancer. TASQ is currently in Phase I clinical trials in
prostate cancer patients.
Phase II studies are scheduled to commence during 2007.
The tumor growth of a series of human prostate cancer xenografts in
male nude mice given nothing vs. TASQ alone, or in combination with
androgen ablation or with androgen ablation plus docetaxel
(Taxotere®), were evaluated. Daily oral treatment with TASQ
consistently inhibited the tumor growth of all of the six xenograft
models tested in a dose dependent manner via an anti-angiogenic
response. TASQ's anti-prostate cancer efficacy was enhanced when
combined with androgen ablation or with androgen ablation plus
docetaxel. The results also documented that differences in serum PSA
in TASQ treated hosts vs. controls are related to inhibition of tumor
growth.
This indicates that in humans, changes in PSA velocity or doubling
time may indicate a therapeutic response to TASQ.
Lund, March 27, 2007
Active Biotech AB (publ)
Sven Andréasson
President and CEO
* "The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod,
enhances the anti-prostate cancer efficacy of androgen ablation and
Taxotere without effecting serum PSA directly in human xenografts" ,
Dalrymple SL, Becker RE, Isaacs JT.
(PMID: 17373719, pre-available as an e-publication at NCBI National
Center for Biotechnology, http://www.ncbi.nlm.nih.gov/).
Active Biotech AB is a biotechnology company focusing on research and
development of pharmaceuticals. Active Biotech has a strong R&D
portfolio with pipeline products focused on autoimmune/inflammatory
diseases and cancer. Most advanced projects are laquinimod, an orally
administered small molecule with unique immunomodulatory properties
for the treatment of multiple sclerosis, as well as ANYARA for use in
cancer immunotherapy with the primary indication non-small cell lung
cancer. Further key projects in clinical development comprise the
three orally administered compounds TASQ for prostate cancer 57-57
for SLE and RhuDex® for RA. In addition, the preclinical development
of the I-3D project is being conducted in cooperation with Chelsea
Therapeutics.
Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46-19 20 00
Fax: +46 46-19 20 50
www.activebiotech.com
Copyright © Hugin ASA 2007. All rights reserved.
